Video

Dr. Kuo on PSMA-PET imaging biomarker research

Author(s):

Urology Times staff

Phillip Kuo, MD, PhD, Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.

The post-hoc exploratory analysis specifically showed that a higher whole-body SUVmean was strongly associated with improved long-term clinical outcomes among men in the VISION trial with PSMA-positive mCRPC on 68Ga-PSMA-11 PET/CT treated with 177Lu-PSMA-617.

Related Videos
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Related Content
Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation
Published: October 4th 2024 | Updated: October 4th 2024

Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation

Urology Times staff
"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Collaboration aims to streamline prostate MRI interpretation, fusion biopsy guidance
September 25th 2024

Collaboration aims to streamline prostate MRI interpretation, fusion biopsy guidance

Hannah Clarke
With this integration, imaging data from the DeepHealth software can be readily imported to the Trinity 3D Ultrasound Platform for prostate fusion biopsy.
Imaging study offers insights on mechanism behind BCG resistance in NMIBC
September 22nd 2024

Imaging study offers insights on mechanism behind BCG resistance in NMIBC

Hannah Clarke
"Interestingly, the findings from this study have already translated into an investigator-initiated clinical trial," says John P. Sfakianos, MD.
PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
September 20th 2024

PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer

Hannah Clarke
“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," the authors write.
PSMA-PET by PROMISE criteria shows prognostic value across prostate cancer continuum
September 20th 2024

PSMA-PET by PROMISE criteria shows prognostic value across prostate cancer continuum

Hannah Clarke
“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," wrote the authors.
© 2024 MJH Life Sciences

All rights reserved.